Boehringer Ingelheim announced today that the FIBRONEER™-ILD trial met its primary endpoint, which was the absolute change from baseline in forced vital capacity (FVC) [mL] at week 52 versus placebo. FVC is a measure of lung function. [i] Initial data readouts of the FIBRONEER™-trials support a
Boehringer
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, in collaboration with the Dubai Health Authority (DHA), sets a Guinness World Records™ title for creating the “Largest light mosaic (image)”. Assembled at Dubai Festival City Mall on November 16th, the mosaic illuminated the connections between cardiovascular, renal, and metabolic (CRM) diseases.











